Back

Early treatment of heart failure: a non-interventional observational study programme of patients with heart failure and initiated on dapagliflozin (EVOLUTION HF)

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 3 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Samuel Adamsson Eryd

AstraZeneca, Gothenburg (Sweden)

6 More presentations in this session

Presentation thumbnail
How low can early introduction of evidence based heart failure medications drive readmission rates?
Doctor T. Caspi (London, GB)
Abstract Slides
Presentation thumbnail
Heart rate management practices in HFrEF among Indian cardiologists: Role of beta-blocker and ivabradine-based therapy
Doctor V. Kolapkar (Thane, IN)
Abstract Slides
Presentation thumbnail
Myocardial ketone body oxidation underlies the salutary effects of SGLT2 inhibitor treatment in heart failure
Ms S. Voorrips (Groningen, NL)
Abstract Slides
Presentation thumbnail
The effect of add-on Ivabradine in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials and real-world data
Doctor C. Liao (Tainan, TW)
Abstract Slides
Presentation thumbnail
How much can ejection fraction be improved in patients with heart failure with reduced ejection fraction (HFrEF) by the early introduction of evidence-based heart failure medication?
Doctor J. White (London, GB)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 3

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources